Cardiomyocyte-specific transforming growth factor β suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction

Circulation Research

Volumn 114, Issue 8, 2014, Pages 1246-1257

  Rainer, Peter P ^a,b   Hao, Scarlett ^a   Vanhoutte, Davy ^c   Lee, Dong Ik ^a   Koitabashi, Norimichi ^a,d   Molkentin, Jeffery D ^c   Kass, David A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF CINCINNATI   (United States)

^d GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

heart rupture; inflammation; myocardial infarction; neutrophils; transforming growth factor beta

Indexed keywords

HEART RUPTURE; INFLAMMATION; MYOCARDIAL INFARCTION; NEUTROPHILS; TRANSFORMING GROWTH FACTOR BETA;

ANIMALS; CELL MOVEMENT; CYTOPROTECTION; DISEASE MODELS, ANIMAL; FOLLISTATIN-RELATED PROTEINS; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NEUTROPHILS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SURVIVAL RATE; THROMBOSPONDINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84899093944     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.302653     Document Type: Article

References (56)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-2128.
2. Huber K, Goldstein P, Danchin N, Fox KA, Welsh R, Granger CB, Henry T, Gersh BJ. Enhancing the effcacy of delivering reperfusion therapy: a European and North American experience with ST-segment elevation myocardial infarction networks. Am Heart J. 2013;165:123-132.
3. Jung K, Kim P, Leuschner F, Gorbatov R, Kim JK, Ueno T, Nahrendorf M, Yun SH. Endoscopic time-lapse imaging of immune cells in infarcted mouse hearts. Circ Res. 2013;112:891-899.
4. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myo-cardial infarction, and heart failure. Science. 2013;339:161-166.
5. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal. 2006;8:1907-1939.
6. Vinten-Johansen J. Involvement of neutrophils in the pathogen-esis of lethal myocardial reperfusion injury. Cardiovasc Res. 2004; 61:481-497.
7. Furman MI, Becker RC, Yarzebski J, Savegeau J, Gore JM, Goldberg RJ. Effect of elevated leukocyte count on in-hospital mortality following acute myocardial infarction. Am J Cardiol. 1996;78:945-948.
8. Barron HV, Harr SD, Radford MJ, Wang Y, Krumholz HM. The association between white blood cell count and acute myocardial infarction mortality in patients > or =65 years of age: fndings from the cooperative cardiovascular project. J Am Coll Cardiol. 2001;38:1654-1661.
9. Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, Renlund DG, Muhlestein JB. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol. 2005;45:1638-1643
10. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007;74:184-195.
11. Koitabashi N, Danner T, Zaiman AL, Pinto YM, Rowell J, Mankowski J, Zhang D, Nakamura T, Takimoto E, Kass DA. Pivotal role of cardio-myocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J Clin Invest. 2011;121:2301-2312.
12. Massague J. Tgfbeta signalling in context. Nat Rev Mol Cell Biol. 2012;13:616-630
13. Lefer AM, Tsao P, Aoki N, Palladino MA Jr. Mediation of cardioprotec-tion by transforming growth factor-beta. Science. 1990;249:61-64.
14. Ikeuchi M, Tsutsui H, Shiomi T, Matsusaka H, Matsushima S, Wen J, Kubota T, Takeshita A. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res. 2004;64:526-535.
15. Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, Lonning S, Ling H, Ertl G, Bauersachs J. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol. 2008;103:485-492.
16. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998;16:137-161.
17. Wahl SM, Hunt DA, Wakefeld LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA. 1987;84:5788-5792.
18. Reibman J, Meixler S, Lee TC, Gold LI, Cronstein BN, Haines KA, Kolasinski SL, Weissmann G. Transforming growth factor beta 1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways. Proc Natl Acad Sci USA. 1991;88:6805-6809.
19. Kitamura M. Identifcation of an inhibitor targeting macrophage production of monocyte chemoattractant protein-1 as TGF-beta 1. J Immunol. 1997;159:1404-1411.
20. Werner F, Jain MK, Feinberg MW, Sibinga NE, Pellacani A, Wiesel P, Chin MT, Topper JN, Perrella MA, Lee ME. Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via Smad3. J Biol Chem. 2000;275:36653-36658.
21. Seo K, Rainer PP, Shalkey Hahn V, Lee DI, Jo SH, Andersen A, Liu T, Xu X, Willette RN, Lepore JJ, Marino JP Jr, Birnbaumer L, Schnackenberg CG, Kass DA. Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy. Proc Natl Acad Sci USA. 2014;111:1551-1556.
22. Raman V, Artemov D, Pathak AP, Winnard PT Jr, McNutt S, Yudina A, Bogdanov A Jr, Bhujwalla ZM. Characterizing vascular parameters in hy-poxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res. 2006;66:9929-9936.
23. He BJ, Joiner ML, Singh MV, et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med. 2011;17:1610-1618.
24. Romanic AM, Burns-Kurtis CL, Gout B, Berrebi-Bertrand I, Ohlstein EH. Matrix metalloproteinase expression in cardiac myocytes following myo-cardial infarction in the rabbit. Life Sci. 2001;68:799-814.
25. Lindsey M, Wedin K, Brown MD, Keller C, Evans AJ, Smolen J, Burns AR, Rossen RD, Michael L, Entman M. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metallopro-teinase 9 in myocardial ischemia/reperfusion. Circulation. 2001;103: 2181-2187.
26. Frangogiannis NG, Ren G, Dewald O, Zymek P, Haudek S, Koerting A, Winkelmann K, Michael LH, Lawler J, Entman ML. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocar-dial infarcts. Circulation. 2005;111:2935-2942.
27. Schroen B, Heymans S, Sharma U, et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifes failure-prone cardiac hypertrophy. Circ Res. 2004;95:515-522.
28. Lynch JM, Maillet M, Vanhoutte D, et al. A thrombospondin-depen-dent pathway for a protective ER stress response. Cell. 2012;149: 1257-1268.
29. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Küchler AM. Interleukin-33-cytokine of dual function or novel alarmin? Trends Immunol. 2009;30:227-233.
30. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardiopro-tective signaling system. J Clin Invest. 2007;117:1538-1549.
31. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2:684-691.
32. Rui T, Tang Q. IL-33 attenuates anoxia/reoxygenation-induced cardiomyocyte apoptosis by inhibition of PKCβ/JNK pathway. PLoS One. 2013;8:e56089.
33. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfu-sion injury. Circ Res. 2006;98:351-360.
34. Widera C, Giannitsis E, Kempf T, Korf-Klingebiel M, Fiedler B, Sharma S, Katus HA, Asaumi Y, Shimano M, Walsh K, Wollert KC. Identifcation of follistatin-like 1 by expression cloning as an activator of the growth differentiation factor 15 gene and a prognostic biomarker in acute coronary syndrome. Clin Chem. 2012;58:1233-1241.
35. Kempf T, Zarbock A, Widera C, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011;17:581-588.
36. Okada H, Takemura G, Kosai K, Li Y, Takahashi T, Esaki M, Yuge K, Miyata S, Maruyama R, Mikami A, Minatoguchi S, Fujiwara T, Fujiwara H. Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure. Circulation. 2005;111:2430-2437.
37. Tan SM, Zhang Y, Connelly KA, Gilbert RE, Kelly DJ. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol. 2010;298:H1415-H1425.
38. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216.
39. Matzinger P. An innate sense of danger. Ann N Y Acad Sci. 2002;961:341-342.
40. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81:1-5.
41. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5:1135-1142.
42. Shimano M, Ouchi N, Walsh K. Cardiokines: recent progress in elucidating the cardiac secretome. Circulation. 2012;126:e327-e332.
43. Alves-Filho JC, Sônego F, Souto FO, Freitas A, Verri WA Jr, Auxiliadora-Martins M, Basile-Filho A, McKenzie AN, Xu D, Cunha FQ, Liew FY. Interleukin-33 attenuates sepsis by enhancing neutrophil infux to the site of infection. Nat Med. 2010;16:708-712.
44. Kempuraj D, Twait EC, Williard DE, Yuan Z, Meyerholz DK, Samuel I. The novel cytokine interleukin-33 activates acinar cell proinfammatory pathways and induces acute pancreatic infammation in mice. PLoS One. 2013;8:e56866.
45. Liew FY. IL-33: a Janus cytokine. Ann Rheum Dis. 2012;71(suppl 2):i101-i104.
46. Abston ED, Barin JG, Cihakova D, Bucek A, Coronado MJ, Brandt JE, Bedja D, Kim JB, Georgakopoulos D, Gabrielson KL, Mitzner W, Fairweather D. IL-33 independently induces eosinophilic pericarditis and cardiac dilation: ST2 improves cardiac function. Circ Heart Fail. 2012;5:366-375.
47. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7:827-840.
48. Rui T, Zhang J, Xu X, Yao Y, Kao R, Martin CM. Reduction in IL-33 expression exaggerates ischaemia/reperfusion-induced myocardial injury in mice with diabetes mellitus. Cardiovasc Res. 2012;94:370-378.
49. Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macro-phage inhibitory cytokine, is a divergent member of the TGF-beta super-family. Proc Natl Acad Sci USA. 1997;94:11514-11519.
50. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006;98:342-350.
51. Ogura Y, Ouchi N, Ohashi K, et al. Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models. Circulation. 2012;126: 1728-1738.
52. Oshima Y, Ouchi N, Sato K, Izumiya Y, Pimentel DR, Walsh K. Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation. 2008;117:3099-3108.
53. Glembotski CC, Thuerauf DJ, Huang C, Vekich JA, Gottlieb RA, Doroudgar S. Mesencephalic astrocyte-derived neurotrophic factor protects the heart from ischemic damage and is selectively secreted upon sarco/endoplasmic reticulum calcium depletion. J Biol Chem. 2012;287: 25893-25904.
54. Tadimalla A, Belmont PJ, Thuerauf DJ, Glassy MS, Martindale JJ, Gude N, Sussman MA, Glembotski CC. Mesencephalic astrocyte-derived neu-rotrophic factor is an ischemia-inducible secreted endoplasmic reticulum stress response protein in the heart. Circ Res. 2008;103:1249-1258.
55. Cingolani OH, Kirk JA, Seo K, Koitabashi N, Lee DI, Ramirez-Correa G, Bedja D, Barth AS, Moens AL, Kass DA. Thrombospondin-4 is required for stretch-mediated contractility augmentation in cardiac muscle. Circ Res. 2011;109:1410-1414.
56. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human infammatory diseases. Proc Natl Acad Sci USA. 2013;110:3507-3512